Andrew E. Aplin

1.2k total citations
22 papers, 722 citations indexed

About

Andrew E. Aplin is a scholar working on Molecular Biology, Oncology and Cell Biology. According to data from OpenAlex, Andrew E. Aplin has authored 22 papers receiving a total of 722 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Molecular Biology, 14 papers in Oncology and 5 papers in Cell Biology. Recurrent topics in Andrew E. Aplin's work include Melanoma and MAPK Pathways (17 papers), HER2/EGFR in Cancer Research (5 papers) and CAR-T cell therapy research (4 papers). Andrew E. Aplin is often cited by papers focused on Melanoma and MAPK Pathways (17 papers), HER2/EGFR in Cancer Research (5 papers) and CAR-T cell therapy research (4 papers). Andrew E. Aplin collaborates with scholars based in United States, Poland and Switzerland. Andrew E. Aplin's co-authors include Yongping Shao, Edward J. Hartsough, Kevin J. Basile, Ha Linh Vu, Paolo Fortina, Fred M. Kaplan, Ethan V. Abel, Adam Ertel, Giorgos C. Karakousis and Xiaowei Xu and has published in prestigious journals such as Journal of Clinical Investigation, Cancer Research and British Journal of Cancer.

In The Last Decade

Andrew E. Aplin

21 papers receiving 719 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew E. Aplin United States 15 604 363 106 104 91 22 722
Madhavi Tadi United States 7 849 1.4× 429 1.2× 96 0.9× 138 1.3× 175 1.9× 7 1.0k
Mary J. C. Ludlam United States 6 673 1.1× 259 0.7× 222 2.1× 63 0.6× 70 0.8× 8 937
Michael B. Atkins United States 9 507 0.8× 507 1.4× 163 1.5× 66 0.6× 39 0.4× 14 761
Edward J. Hartsough United States 16 670 1.1× 292 0.8× 200 1.9× 75 0.7× 65 0.7× 21 845
T. Ahmad United Kingdom 7 566 0.9× 388 1.1× 87 0.8× 82 0.8× 78 0.9× 12 677
Maggie James United States 8 568 0.9× 412 1.1× 99 0.9× 78 0.8× 80 0.9× 25 721
Allison Marlow United States 3 724 1.2× 447 1.2× 44 0.4× 98 0.9× 166 1.8× 3 946
Marian M. Deuker United States 6 580 1.0× 274 0.8× 56 0.5× 117 1.1× 118 1.3× 6 742
Zoi Karoulia United States 6 560 0.9× 238 0.7× 65 0.6× 115 1.1× 130 1.4× 9 664
Curtis H. Kugel United States 8 382 0.6× 239 0.7× 69 0.7× 54 0.5× 51 0.6× 8 461

Countries citing papers authored by Andrew E. Aplin

Since Specialization
Citations

This map shows the geographic impact of Andrew E. Aplin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew E. Aplin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew E. Aplin more than expected).

Fields of papers citing papers by Andrew E. Aplin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew E. Aplin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew E. Aplin. The network helps show where Andrew E. Aplin may publish in the future.

Co-authorship network of co-authors of Andrew E. Aplin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew E. Aplin. A scholar is included among the top collaborators of Andrew E. Aplin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew E. Aplin. Andrew E. Aplin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Lubrano, Simone, Farhoud Faraji, Rodolfo Daniel Cervantes‐Villagrana, et al.. (2024). Abstract 4745: A novel combination therapy targeting RAF, MEK and FAK to overcome skin cutaneous melanoma treatment resistance. Cancer Research. 84(6_Supplement). 4745–4745. 1 indexed citations
2.
Caksa, Signe, et al.. (2022). The future of targeted kinase inhibitors in melanoma. Pharmacology & Therapeutics. 239. 108200–108200. 27 indexed citations
3.
Tiago, Manoela, Claudia Capparelli, Dan A. Erkes, et al.. (2020). Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma. British Journal of Cancer. 122(6). 789–800. 13 indexed citations
4.
Petit, Valérie, Christophe Alberti, Stuart Gallagher, et al.. (2019). C57BL/6 congenic mouse NRASQ61K melanoma cell lines are highly sensitive to the combination of Mek and Akt inhibitors in vitro and in vivo. Pigment Cell & Melanoma Research. 32(6). 829–841. 24 indexed citations
5.
Emmons, Michael F., Fernanda Faião‐Flores, Andrew E. Aplin, et al.. (2019). Decitabine limits escape from MEK inhibition in uveal melanoma. Pigment Cell & Melanoma Research. 33(3). 507–514. 21 indexed citations
6.
Teh, Jessica L.F., Phil F. Cheng, Timothy J. Purwin, et al.. (2018). In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms. Cancer Discovery. 8(5). 568–581. 61 indexed citations
7.
Brożyna, Anna A., Andrew E. Aplin, Cynthia Cohen, et al.. (2017). CKS1 expression in melanocytic nevi and melanoma. Oncotarget. 9(3). 4173–4187. 1 indexed citations
8.
Teh, Jessica L.F., Timothy J. Purwin, Evan J. Greenawalt, et al.. (2016). An In Vivo Reporter to Quantitatively and Temporally Analyze the Effects of CDK4/6 Inhibitor-Based Therapies in Melanoma. Cancer Research. 76(18). 5455–5466. 23 indexed citations
9.
Vu, Ha Linh, Sheera R. Rosenbaum, Claudia Capparelli, et al.. (2015). MIG6 Is MEK Regulated and Affects EGF-Induced Migration in Mutant NRAS Melanoma. Journal of Investigative Dermatology. 136(2). 453–463. 12 indexed citations
10.
Capparelli, Claudia, Sheera R. Rosenbaum, Lisa D. Berman-Booty, et al.. (2015). ErbB3–ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas. Cancer Research. 75(17). 3554–3567. 18 indexed citations
11.
Hartsough, Edward J., Kevin J. Basile, & Andrew E. Aplin. (2014). Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant–Expressing Melanoma. Molecular Cancer Research. 12(5). 795–802. 19 indexed citations
12.
Vu, Ha Linh & Andrew E. Aplin. (2014). Targeting TBK1 Inhibits Migration and Resistance to MEK Inhibitors in Mutant NRAS Melanoma. Molecular Cancer Research. 12(10). 1509–1519. 47 indexed citations
13.
Basile, Kevin J., et al.. (2013). In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors. Cancer Research. 73(23). 7101–7110. 30 indexed citations
14.
Hartsough, Edward J., Yongping Shao, & Andrew E. Aplin. (2013). Resistance to RAF Inhibitors Revisited. Journal of Investigative Dermatology. 134(2). 319–325. 62 indexed citations
15.
Abel, Ethan V., Kevin J. Basile, Curtis H. Kugel, et al.. (2013). Melanoma adapts to RAF/MEK inhibitors through FOXD3-mediated upregulation of ERBB3. Journal of Clinical Investigation. 123(5). 2155–2168. 189 indexed citations
16.
Blomain, Erik, et al.. (2013). Selective RAF inhibitor impairs ERK1/2 phosphorylation and growth in mutant NRAS, vemurafenib‐resistant melanoma cells. Pigment Cell & Melanoma Research. 26(4). 509–517. 54 indexed citations
17.
Vu, Ha Linh & Andrew E. Aplin. (2012). The Yin‐Yang of RAF inhibitors. Pigment Cell & Melanoma Research. 25(2). 127–128.
18.
Basile, Kevin J. & Andrew E. Aplin. (2012). Downregulation of Noxa by RAF/MEK inhibition counteracts cell death response in mutant B-RAF melanoma cells.. PubMed. 2(6). 726–35. 16 indexed citations
19.
Aplin, Andrew E., Fred M. Kaplan, & Yongping Shao. (2011). Mechanisms of Resistance to RAF Inhibitors in Melanoma. Journal of Investigative Dermatology. 131(9). 1817–1820. 62 indexed citations
20.
Smalley, Keiran S.M., Andrew E. Aplin, Keith T. Flaherty, et al.. (2011). Meeting report from the 2011 international melanoma congress, Tampa, Florida. Pigment Cell & Melanoma Research. 25(1). E1–11. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Madhavi Tadi Breakdown of academic impact, for papers by Mary J. C. Ludlam Breakdown of academic impact, for papers by Michael B. Atkins Breakdown of academic impact, for papers by Edward J. Hartsough Breakdown of academic impact, for papers by T. Ahmad Breakdown of academic impact, for papers by Maggie James Breakdown of academic impact, for papers by Allison Marlow Breakdown of academic impact, for papers by Marian M. Deuker Breakdown of academic impact, for papers by Zoi Karoulia Breakdown of academic impact, for papers by Curtis H. Kugel
Rankless by CCL
2026